NCI-2024-04600

A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating The Safety, Pharmacokinetics, and Activity of RO7566802 as Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

This is a Phase I study testing the safety, how the body processes, and how well a drug called RO7566802 works on its own and when combined with another drug called Atezolizumab. The study is for patients with advanced or metastatic solid tumors, such as cancers that start in organs like the lungs, breast, or liver. The goal is to understand how safe these drugs are, how they behave in the body, and if they can help treat cancer.

Phase I: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06031441

Clinical Trial Site: Sinai

To see all available clinical trials click here.